News
The Food and Drug Administration has placed a clinical hold on Gilead’s (GILD) HIV treatment trials of GS-1720 and/or GS-4182 ...
Gilead has been hit with a clinical hold from the FDA for five tests of its experimental HIV combination treatment amid ...
GILD slides 2.6% after FDA halts trials for HIV candidates, GS-1720 and GS-4182, over safety concerns in patients.
1d
Clinical Trials Arena on MSNGilead hit with FDA clinical hold for batch of HIV trialsDecreasing CD4 and lymphocyte counts in some participants receiving an oral combination therapy led to holds in the study.
Gilead Sciences has announced that the U.S. Food and Drug Administration has placed a clinical hold on its HIV treatment ...
Gilead’s HIV treatment trials involving an investigational integrase strand inhibitor (GS-1720) and an investigational capsid inhibitor (GS-4182) have been put on clinical hold by the Food and Drug ...
On some negative news about one of its investigational programs, the stock of pharmaceutical company Gilead Sciences (NASDAQ: ...
Gilead underscored its faith in the combo therapy and pledged to work with regulators to resolve the hold, which has paused ...
Gilead Sciences said the U.S. Food and Drug Administration has placed a clinical hold on studies of an investigational weekly HIV pill combination over signs of potentially weakened immune systems ...
The U.S. Food and Drug Administration has placed a clinical hold on Gilead Sciences' trials testing a combination of two of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results